ACS Publications. Most Trusted. Most Cited. Most Read
My Activity

Figure 1Loading Img

Development of a Clinically Viable Heroin Vaccine

View Author Information
Departments of Chemistry and Immunology, The Skaggs Institute for Chemical Biology, Worm Institute of Research and Medicine (WIRM), The Scripps Research Institute, 10550 N Torrey Pines Road, La Jolla, California 92037, United States
Department of Pharmacology and Toxicology, Virginia Commonwealth University, 410 N 12th Street, Richmond, Virginia 23298, United States
Cite this: J. Am. Chem. Soc. 2017, 139, 25, 8601–8611
Publication Date (Web):June 2, 2017
Copyright © 2017 American Chemical Society

    Article Views





    Other access options
    Supporting Info (1)»


    Abstract Image

    Heroin is a highly abused opioid and incurs a significant detriment to society worldwide. In an effort to expand the limited pharmacotherapy options for opioid use disorders, a heroin conjugate vaccine was developed through comprehensive evaluation of hapten structure, carrier protein, adjuvant and dosing. Immunization of mice with an optimized heroin-tetanus toxoid (TT) conjugate formulated with adjuvants alum and CpG oligodeoxynucleotide (ODN) generated heroin “immunoantagonism”, reducing heroin potency by >15-fold. Moreover, the vaccine effects proved to be durable, persisting for over eight months. The lead vaccine was effective in rhesus monkeys, generating significant and sustained antidrug IgG titers in each subject. Characterization of both mouse and monkey antiheroin antibodies by surface plasmon resonance (SPR) revealed low nanomolar antiserum affinity for the key heroin metabolite, 6-acetylmorphine (6AM), with minimal cross reactivity to clinically used opioids. Following a series of heroin challenges over six months in vaccinated monkeys, drug-sequestering antibodies caused marked attenuation of heroin potency (>4-fold) in a schedule-controlled responding (SCR) behavioral assay. Overall, these preclinical results provide an empirical foundation supporting the further evaluation and potential clinical utility of an effective heroin vaccine in treating opioid use disorders.

    Read this article

    To access this article, please review the available access options below.

    Get instant access

    Purchase Access

    Read this article for 48 hours. Check out below using your ACS ID or as a guest.


    Access through Your Institution

    You may have access to this article through your institution.

    Your institution does not have access to this content. You can change your affiliated institution below.

    Supporting Information

    Jump To

    The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/jacs.7b03334.

    • Materials and methods, conjugate mass data, titer data, additional mouse and monkey vaccine data: Tables S1–S2, Figures S1–S10 (PDF)

    Terms & Conditions

    Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:

    Cited By

    This article is cited by 72 publications.

    1. Fatemeh Shafieichaharberoud, Shuyao Lang, Connor Whalen, Cristina Rivera Quiles, Lillie Purcell, Cameron Talbot, Pengfei Wang, Elizabeth B. Norton, Michelle Mazei-Robison, Agnieszka Sulima, Arthur E. Jacobson, Kenner C. Rice, Gary R. Matyas, Xuefei Huang. Enhancing Protective Antibodies against Opioids through Antigen Display on Virus-like Particles. Bioconjugate Chemistry 2024, 35 (2) , 164-173.
    2. Mingliang Lin, Alexander Marin, Beverly Ellis, Lisa M. Eubanks, Alexander K. Andrianov, Kim D. Janda. Polyphosphazene: A New Adjuvant Platform for Cocaine Vaccine Development. Molecular Pharmaceutics 2022, 19 (9) , 3358-3366.
    3. Mingliang Lin, Jinny Claire Lee, Steven Blake, Beverly Ellis, Lisa M. Eubanks, Kim D. Janda. Broadly Neutralizing Synthetic Cannabinoid Vaccines. JACS Au 2021, 1 (1) , 31-40.
    4. Steven Blake, Paul T. Bremer, Bin Zhou, Nikolai Petrovsky, Lauren C. Smith, Candy S. Hwang, Kim D. Janda. Developing Translational Vaccines against Heroin and Fentanyl through Investigation of Adjuvants and Stability. Molecular Pharmaceutics 2021, 18 (1) , 228-235.
    5. Christine Robinson, Valeria Gradinati, Fatima Hamid, Carly Baehr, Bethany Crouse, Saadyah Averick, Marina Kovaliov, Danni Harris, Scott Runyon, Federico Baruffaldi, Mark LeSage, Sandra Comer, Marco Pravetoni. Therapeutic and Prophylactic Vaccines to Counteract Fentanyl Use Disorders and Toxicity. Journal of Medicinal Chemistry 2020, 63 (23) , 14647-14667.
    6. Jaime Mella-Raipán, Javier Romero-Parra, Gonzalo Recabarren-Gajardo. DARK Classics in Chemical Neuroscience: Heroin and Desomorphine. ACS Chemical Neuroscience 2020, 11 (23) , 3905-3927.
    7. Jillian L. Kyzer, Mason McGuire, Hyeri Park, Tyson F. Belz, Robert Bonakdar, Kim D. Janda, Cody J. Wenthur. Anti-Opioid Antibodies in Individuals Using Chronic Opioid Therapy for Lower Back Pain. ACS Pharmacology & Translational Science 2020, 3 (5) , 896-906.
    8. Tyson F. Belz, Paul T. Bremer, Bin Zhou, Beverly Ellis, Lisa M. Eubanks, Kim D. Janda. Enhancement of a Heroin Vaccine through Hapten Deuteration. Journal of the American Chemical Society 2020, 142 (31) , 13294-13298.
    9. Lauren C. Smith, Paul T. Bremer, Candy S. Hwang, Bin Zhou, Beverly Ellis, Mark S. Hixon, Kim D. Janda. Monoclonal Antibodies for Combating Synthetic Opioid Intoxication. Journal of the American Chemical Society 2019, 141 (26) , 10489-10503.
    10. Robin J. Prince, Fang Gao, Jessica E. Pazienza, Isaac E. Marx, Jurgen Schulz, Brian T. Hopkins. Utilization of Cyclic Amides as Masked Aldehyde Equivalents in Reductive Amination Reactions. The Journal of Organic Chemistry 2019, 84 (12) , 7936-7949.
    11. F. Baruffaldi, M. D. Raleigh, S. J. King, M. J. Roslawski, A. K. Birnbaum, C. Hassler, F. I. Carroll, S. P. Runyon, S. Winston, P. R. Pentel, M. Pravetoni. Formulation and Characterization of Conjugate Vaccines to Reduce Opioid Use Disorders Suitable for Pharmaceutical Manufacturing and Clinical Evaluation. Molecular Pharmaceutics 2019, 16 (6) , 2364-2375.
    12. Margaret E. Olson, Lisa M. Eubanks, Kim D. Janda. Chemical Interventions for the Opioid Crisis: Key Advances and Remaining Challenges. Journal of the American Chemical Society 2019, 141 (5) , 1798-1806.
    13. Jake Jaffe, Kristin Wucherer, Justin Sperry, Qin Zou, Qing Chang, Mark A. Massa, Keshab Bhattacharya, Sandeep Kumar, Maire Caparon, David Stead, Paul Wright, Anouk Dirksen, Matthew B. Francis. Effects of Conformational Changes in Peptide–CRM197 Conjugate Vaccines. Bioconjugate Chemistry 2019, 30 (1) , 47-53.
    14. Federico Baruffaldi, April Huseby Kelcher, Megan Laudenbach, Valeria Gradinati, Ajinkya Limkar, Michaela Roslawski, Angela Birnbaum, Andrew Lees, Carla Hassler, Scott Runyon, Marco Pravetoni. Preclinical Efficacy and Characterization of Candidate Vaccines for Treatment of Opioid Use Disorders Using Clinically Viable Carrier Proteins. Molecular Pharmaceutics 2018, 15 (11) , 4947-4962.
    15. Candy S. Hwang, Lauren C. Smith, Yoshihiro Natori, Beverly Ellis, Bin Zhou, Kim D. Janda. Improved Admixture Vaccine of Fentanyl and Heroin Hapten Immunoconjugates: Antinociceptive Evaluation of Fentanyl-Contaminated Heroin. ACS Omega 2018, 3 (9) , 11537-11543.
    16. Candy S. Hwang, Lauren C. Smith, Yoshihiro Natori, Beverly Ellis, Bin Zhou, Kim D. Janda. Efficacious Vaccine against Heroin Contaminated with Fentanyl. ACS Chemical Neuroscience 2018, 9 (6) , 1269-1275.
    17. Candy S. Hwang, Paul T. Bremer, Cody J. Wenthur, Sam On Ho, SuMing Chiang, Beverly Ellis, Bin Zhou, Gary Fujii, Kim D. Janda. Enhancing Efficacy and Stability of an Antiheroin Vaccine: Examination of Antinociception, Opioid Binding Profile, and Lethality. Molecular Pharmaceutics 2018, 15 (3) , 1062-1072.
    18. Agnieszka Sulima, Rashmi Jalah, Joshua F. G. Antoline, Oscar B. Torres, Gregory H. Imler, Jeffrey R. Deschamps, Zoltan Beck, Carl R. Alving, Arthur E. Jacobson, Kenner C. Rice, and Gary R. Matyas . A Stable Heroin Analogue That Can Serve as a Vaccine Hapten to Induce Antibodies That Block the Effects of Heroin and Its Metabolites in Rodents and That Cross-React Immunologically with Related Drugs of Abuse. Journal of Medicinal Chemistry 2018, 61 (1) , 329-343.
    19. Candy S. Hwang and Kim D. Janda . A Vision for Vaccines: Combating the Opioid Epidemic. Biochemistry 2017, 56 (42) , 5625-5627.
    20. Tangsheng Lu, Xue Li, Wei Zheng, Chenyan Kuang, Bingyi Wu, Xiaoxing Liu, Yanxue Xue, Jie Shi, Lin Lu, Ying Han. Vaccines to Treat Substance Use Disorders: Current Status and Future Directions. Pharmaceutics 2024, 16 (1) , 84.
    21. Shannon M. Miller, Bethany Crouse, Linda Hicks, Hardik Amin, Shelby Cole, Helene G. Bazin, David J. Burkhart, Marco Pravetoni, Jay T. Evans. A lipidated TLR7/8 adjuvant enhances the efficacy of a vaccine against fentanyl in mice. npj Vaccines 2023, 8 (1)
    22. Mark Anthony Leon Duque, Nandini Vallavoju, Christina M. Woo. Chemical tools for the opioids. Molecular and Cellular Neuroscience 2023, 125 , 103845.
    23. Cheng Hua. Drugs For Relapse Prevention in Addiction: Review of Psychological and Neurological Factors, Genetics and Neurobiological Mechanisms. 2023, 158-237.
    24. Susana Barbosa-Méndez, Maura Matus-Ortega, Ricardo Hernández Miramontes, Alberto Salazar-Juárez. The M3-TT Vaccine Decreases the Antinociceptive Effects of Morphine and Heroin in Mice. International Journal of Mental Health and Addiction 2023, 21 (2) , 783-802.
    25. Theofanis Vavilis, Eleni Stamoula, Athanasios Sachinidis, Malamatenia Lamprinou, Ioannis Dardalas, Georgios Papazisis. Biopharmaceuticals against substance use disorders – Present and future. European Journal of Pharmacology 2023, 944 , 175587.
    26. Brenda Molina-Ramírez, Nidia Cabral-Hipólito, Irais Castillo-Maldonado, Dealmy Delgadillo-Guzmán, Rocío Meza-Velázquez, Agustina Ramírez-Moreno, Erika Flores-Loyola, Pablo Ruíz-Flores, Jorge Haro-Santa Cruz, Perla-Karina Espino-Silva, Joaquín Avalos-Soto, Miguel-Ángel Téllez-López, Rubén Daniel Arellano Pérez Vertti, Manuel-Gerardo Rosales-González, David Pedroza-Escobar. Tannic Acid, as a Structural Moiety Coupled to a Protein Antigen, Exhibiting a Molecular-structure Adjuvant Activity for Antibody Specificity Enhancement. Protein & Peptide Letters 2022, 29 (11) , 925-936.
    27. Md Kamal Hossain, Majid Davidson, Erica Kypreos, Jack Feehan, Joshua Alexander Muir, Kulmira Nurgali, Vasso Apostolopoulos. Immunotherapies for the Treatment of Drug Addiction. Vaccines 2022, 10 (11) , 1778.
    28. Adam Worob, Cody J. Wenthur. Development of Cross-Reactive Antibodies for the Identification and Treatment of Synthetic Cannabinoid Receptor Agonist Toxicity. Vaccines 2022, 10 (8) , 1253.
    29. Leonardo da Silva Neto, Angélica Faleiros da Silva Maia, Adriana Martins Godin, Paulo Sérgio de Almeida Augusto, Raissa Lima Gonçalves Pereira, Sordaini Maria Caligiorne, Rosemeire Brondi Alves, Simone Odília Antunes Fernandes, Valbert Nascimento Cardoso, Gisele Assis Castro Goulart, Felipe Terra Martins, Maila de Castro Lourenço das Neves, Frederico Duarte Garcia, Ângelo de Fátima. Calix[n]arene-based immunogens: A new non-proteic strategy for anti-cocaine vaccine. Journal of Advanced Research 2022, 38 , 285-298.
    30. Therese J. Ziaks, Candy S. Hwang. Is it possible to design a clinically viable heroin vaccine? The progress and pitfalls. Expert Opinion on Drug Discovery 2022, 17 (3) , 207-210.
    31. Agnieszka Sulima, Fuying Li, Jeffrey Brian Morgan, Phong Truong, Joshua F. G. Antoline, Therese Oertel, Rodell C. Barrientos, Oscar B. Torres, Zoltan Beck, Gregory H. Imler, Jeffrey R. Deschamps, Gary R. Matyas, Arthur E. Jacobson, Kenner C. Rice. Design, Synthesis, and In Vivo Evaluation of C1-Linked 4,5-Epoxymorphinan Haptens for Heroin Vaccines. Molecules 2022, 27 (5) , 1553.
    32. James Tidder, Alexander M. Baldacchino, Joseph Tay Wee Teck. Medication-Assisted Treatment for Opioid Use Disorders 2: Detoxification. 2022, 343-362.
    33. William M. Meil, William Farrell, Reem Satti. An Evaluation of Diverse Therapeutic Interventions for Substance Use Disorders: Serotonergic Hallucinogens, Immunotherapy, and Transcranial Magnetic Stimulation. 2021
    34. Susana Barbosa-Méndez, Maura Matus-Ortega, Ricardo Hernández-Miramontes, Alberto Salazar-Juárez. The morphine/heroin vaccine decreased the heroin-induced antinociceptive and reinforcing effects in three inbred strains mouse. International Immunopharmacology 2021, 98 , 107887.
    35. Xi-Chao Duan, Huanhuan Cheng, Maia Martcheva, Sanling Yuan. Dynamics of an Age Structured Heroin Transmission Model with Imperfect Vaccination. International Journal of Bifurcation and Chaos 2021, 31 (10) , 2150157.
    36. István Köteles, Károly Mazák, Gergő Tóth, Péter Horváth, Eszter Kiss, Boglárka Tűz, Sándor Hosztafi. Synthesis of 3‐ O ‐Carboxyalkyl Morphine Derivatives and Characterization of Their Acid‐Base Properties. Chemistry & Biodiversity 2021, 18 (7)
    37. Hyeri Park, Jinny Claire Lee, Lisa M. Eubanks, Beverly Ellis, Bin Zhou, Kim D. Janda. Improvements on a chemically contiguous hapten for a vaccine to address fentanyl-contaminated heroin. Bioorganic & Medicinal Chemistry 2021, 41 , 116225.
    38. Tyson F. Belz, Mingliang Lin, Lisa M. Eubanks, Beverly Ellis, Kim D. Janda. Vaccine design through transition state mimicry of heroin hydrolysis. Tetrahedron Letters 2021, 71 , 153045.
    39. Lyn H. Jones. Medicinal Chemical Biology. 2021, 1-37.
    40. Sumanth Kuppalli, Raghav Seth, Vwaire Orhurhu, Ivan Urits, Alan D. Kaye, Corey Hunter, Amitabh Gulati, Peju Adekoya, Adam M. Kaye, Mark R. Jones. Recent Advances in the Treatment of Opioid Use Disorder. Current Pain and Headache Reports 2021, 25 (4)
    41. F. Ivy Carroll, Anita H. Lewin, S. Wayne Mascarella, Herbert H. Seltzman, P. Anantha Reddy. Designer drugs: a medicinal chemistry perspective (II). Annals of the New York Academy of Sciences 2021, 1489 (1) , 48-77.
    42. Christopher Wicks, Tomas Hudlicky, Uwe Rinner. Morphine alkaloids: History, biology, and synthesis. 2021, 145-342.
    43. Susana Barbosa Méndez, Maura Matus-Ortega, Ricardo Hernández Miramontes, Alberto Salazar-Juárez. Effect of the morphine/heroin vaccine on opioid and non-opioid drug-induced antinociception in mice. European Journal of Pharmacology 2021, 891 , 173718.
    44. E. Andrew Townsend, S. Stevens Negus, Matthew L. Banks. Medications Development for Treatment of Opioid Use Disorder. Cold Spring Harbor Perspectives in Medicine 2021, 11 (1) , a039263.
    45. Carly Baehr, April Huseby Kelcher, Aaron Khaimraj, Dana E. Reed, Sujata G. Pandit, David AuCoin, Saadyah Averick, Marco Pravetoni. Monoclonal Antibodies Counteract Opioid-Induced Behavioral and Toxic Effects in Mice and Rats. Journal of Pharmacology and Experimental Therapeutics 2020, 375 (3) , 469-477.
    46. Morgan Brisse, Sophia M. Vrba, Natalie Kirk, Yuying Liang, Hinh Ly. Emerging Concepts and Technologies in Vaccine Development. Frontiers in Immunology 2020, 11
    47. Tyson F. Belz, Paul T. Bremer, Bin Zhou, Steven Blake, Beverly Ellis, Lisa M. Eubanks, Kim D. Janda. Sulfonate-isosteric replacement examined within heroin-hapten vaccine design. Bioorganic & Medicinal Chemistry Letters 2020, 30 (17) , 127388.
    48. István Köteles, Károly Mazák, Gergő Tóth, Boglárka Tűz, Sándor Hosztafi. Synthesis of Potential Haptens with Morphine Skeleton and Determination of Protonation Constants. Molecules 2020, 25 (17) , 4009.
    49. Yoshihiro Natori, Kim D. Janda. Synthesis of Drug Vaccine against Heroin Contaminated with Fentanyl and Their Biological Evaluation. Journal of Synthetic Organic Chemistry, Japan 2020, 78 (9) , 875-885.
    50. Valeria Gradinati, Federico Baruffaldi, Santhi Abbaraju, Megan Laudenbach, Rasidul Amin, Brian Gilger, Poonam Velagaleti, Marco Pravetoni. Polymer-mediated delivery of vaccines to treat opioid use disorders and to reduce opioid-induced toxicity. Vaccine 2020, 38 (30) , 4704-4712.
    51. E. Andrew Townsend, Matthew L. Banks. Preclinical Evaluation of Vaccines to Treat Opioid Use Disorders: How Close are We to a Clinically Viable Therapeutic?. CNS Drugs 2020, 34 (5) , 449-461.
    52. Tang Xiaoshan, Yang Junjie, Wang Wenqing, Zeng Yunong, Li Jiaping, Lin Shanshan, Nandakumar Kutty Selva, Cheng Kui. Immunotherapy for treating methamphetamine, heroin and cocaine use disorders. Drug Discovery Today 2020, 25 (3) , 610-619.
    53. Samantha J. McClenahan, Chad M. Kormos, Melinda Gunnell, Michael D. Hambuchen, Pamela Lamb, Frank Ivy Carroll, Anita H. Lewin, Eric C. Peterson, Samuel Michael Owens. Design, synthesis and biological evaluation of a bi-specific vaccine against α-pyrrolidinovalerophenone (α-PVP) and 3,4-methylenedioxypyrovalerone (MDPV) in rats. Vaccine 2020, 38 (2) , 336-344.
    54. Octavian Vasiliu, Ileana Marinescu, Daniel Vasile. Therapeutic management of substance use disorders (II). 2020, 1 (60) , 14.
    55. Kathryn L. Schwienteck, Steven Blake, Paul T. Bremer, Justin L. Poklis, E. Andrew Townsend, S. Stevens Negus, Matthew L. Banks. Effectiveness and selectivity of a heroin conjugate vaccine to attenuate heroin, 6-acetylmorphine, and morphine antinociception in rats: Comparison with naltrexone. Drug and Alcohol Dependence 2019, 204 , 107501.
    56. Marco Pravetoni, Sandra D. Comer. Development of vaccines to treat opioid use disorders and reduce incidence of overdose. Neuropharmacology 2019, 158 , 107662.
    57. Rebekah D. Tenney, Steven Blake, Paul T. Bremer, Bin Zhou, Candy S. Hwang, Justin L. Poklis, Kim D. Janda, Matthew L. Banks. Vaccine blunts fentanyl potency in male rhesus monkeys. Neuropharmacology 2019, 158 , 107730.
    58. E. Andrew Townsend, Steven Blake, Kaycee E. Faunce, Candy S. Hwang, Yoshihiro Natori, Bin Zhou, Paul T. Bremer, Kim D. Janda, Matthew L. Banks. Conjugate vaccine produces long-lasting attenuation of fentanyl vs. food choice and blocks expression of opioid withdrawal-induced increases in fentanyl choice in rats. Neuropsychopharmacology 2019, 44 (10) , 1681-1689.
    59. M. Heval Ozgen, Stuart Blume. The continuing search for an addiction vaccine. Vaccine 2019, 37 (36) , 5485-5490.
    60. Candy S. Hwang, Lauren C. Smith, Cody J. Wenthur, Beverly Ellis, Bin Zhou, Kim D. Janda. Heroin vaccine: Using titer, affinity, and antinociception as metrics when examining sex and strain differences. Vaccine 2019, 37 (30) , 4155-4163.
    61. Kinam Park, Andrew Otte. Prevention of Opioid Abuse and Treatment of Opioid Addiction: Current Status and Future Possibilities. Annual Review of Biomedical Engineering 2019, 21 (1) , 61-84.
    62. Christine Robinson, Carly Baehr, Shirdi E. Schmiel, Claudia Accetturo, Daniel L. Mueller, Marco Pravetoni. Alum adjuvant is more effective than MF59 at prompting early germinal center formation in response to peptide-protein conjugates and enhancing efficacy of a vaccine against opioid use disorders. Human Vaccines & Immunotherapeutics 2019, 15 (4) , 909-917.
    63. Michael D. Raleigh, Federico Baruffaldi, Samantha J. Peterson, Morgan Le Naour, Theresa M. Harmon, Jennifer R. Vigliaturo, Paul R. Pentel, Marco Pravetoni. A Fentanyl Vaccine Alters Fentanyl Distribution and Protects against Fentanyl-Induced Effects in Mice and Rats. Journal of Pharmacology and Experimental Therapeutics 2019, 368 (2) , 282-291.
    64. Candy S. Hwang, Beverly Ellis, Bin Zhou, Kim D. Janda. Heat shock proteins: A dual carrier-adjuvant for an anti-drug vaccine against heroin. Bioorganic & Medicinal Chemistry 2019, 27 (1) , 125-132.
    65. Yoshihiro Natori, Candy S Hwang, Lucy Lin, Lauren C Smith, Bin Zhou, Kim D Janda. A chemically contiguous hapten approach for a heroin–fentanyl vaccine. Beilstein Journal of Organic Chemistry 2019, 15 , 1020-1031.
    66. Matthew S. Ellis, Zachary A. Kasper, Theodore J. Cicero. Twin epidemics: The surging rise of methamphetamine use in chronic opioid users. Drug and Alcohol Dependence 2018, 193 , 14-20.
    67. Matthew L. Banks, Margaret E. Olson, Kim D. Janda. Immunopharmacotherapies for Treating Opioid Use Disorder. Trends in Pharmacological Sciences 2018, 39 (11) , 908-911.
    68. Özlem Ertekin, Esin Akçael, Harun Kocaağa, Selma Öztürk. Biological Activity of the Carrier as a Factor in Immunogen Design for Haptens. Molecules 2018, 23 (11) , 2977.
    69. Michael D. Raleigh, Megan Laudenbach, Federico Baruffaldi, Samantha J. Peterson, Michaela J. Roslawski, Angela K. Birnbaum, F. Ivy Carroll, Scott P. Runyon, Scott Winston, Paul R. Pentel, Marco Pravetoni. Opioid Dose- and Route-Dependent Efficacy of Oxycodone and Heroin Vaccines in Rats. Journal of Pharmacology and Experimental Therapeutics 2018, 365 (2) , 346-353.
    70. Mary Bates. Tackling an Epidemic: New and Emerging Opioid Addiction Treatments Offer Hope for Solutions to This Crisis. IEEE Pulse 2018, 9 (2) , 22-25.
    71. Margaret E Olson, Kim D Janda. Vaccines to combat the opioid crisis. EMBO reports 2018, 19 (1) , 5-9.
    72. Paul T. Bremer, Kim D. Janda, . Conjugate Vaccine Immunotherapy for Substance Use Disorder. Pharmacological Reviews 2017, 69 (3) , 298-315.

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    You’ve supercharged your research process with ACS and Mendeley!

    STEP 1:
    Click to create an ACS ID

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Your Mendeley pairing has expired. Please reconnect